News

Dr Amphlett and Dr Lutz have played central roles in establishing ImmunoGen’s product development capabilities. These functions complement the company’s research capabilities in ImmunoGen’s advancement of its own

Dapagliflozin, an investigational compound, is a potential sodium-glucose cotransporter-2 (SGLT2) inhibitor currently in Phase 3 trials under joint development by Bristol-Myers Squibb Company and AstraZeneca. The study also

As per the agreement, OMJPI is expected to get an exclusive worldwide license to manufacture, develop and commercialise several Metabolex programs which are currently at the preclinical stage.

Wellington currently operates from an 116,000sqft facility that is equipped with process automation equipment and is fully compliant with the latest federal regulations. About 80 employees made the

The two new programs added are expected to address the development of four compounds which target different subpopulations of patients suffering from DMD. To access these new programs,

Eribulin is an investigational anticancer agent discovered and developed by Eisai. Eisai filed simultaneous regulatory applications for approval of Eribulin to the health authorities in the US, Japan

The acceptance letter confirms that the Chemistry, Manufacturing and Controls (CMC) response filed by NexMed is acceptable for the final, 150-day review cycle, during which regulatory reviewers are

Pfizer received approval for the single agent Mylotarg, in the US, under FDA’s accelerated approval regulations based on overall response rate in three non-comparative studies and required submission

Takeda Pharma said that the once-daily prescription medication, available in two commonly used dosages of pioglitazone and metformin XR – 15 mg/1000 mg and 30 mg/1000 mg tablets,